Due to the association of 12α-OH BAs in T2DM, obesity, and NAFLD/NASH, immense interest has been generated in the drug discovery of CYP8B1 inhibitors. This evidence concerns the gene CYP8B1 and metabolic dysfunction-associated steatotic liver disease.